source
- Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesityNovo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…
- Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decisionActivist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M…